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Self-assembled micelles of amphiphilic PEGylated
rapamycin for loading paclitaxel and resisting
multidrug resistant cancer cells†
Wei Tian,‡a Jieying Liu,‡a Yuan Guo,b Yuanyuan Shen,a Dejian Zhou*b
and Shengrong Guo*ab
Self-assembled micelles of amphiphilic PEG–rapamycin conjugates
loaded with paclitaxel have been developed for co-delivery and
simultaneous intracellular release of paclitaxel and rapamycin,
bypassing the cancer cell drug resistant mechanism and maximising
the synergy of dual-drug combinational therapy. This novel nano-
medicine oﬀers 20-fold improved potency over free paclitaxel against
a model multidrug resistant human breast cancer cell.
Multidrug resistance (MDR) is a leading cause of chemotherapy
failure in cancer treatment. Overcoming MDR is a tremendous
challenge faced by the pharmaceutical and healthcare indus-
tries currently.1 Over-expressed eﬄux transporter proteins (e.g.
g-glycoprotein, MDR1 and MDR associated proteins) are widely
found on MDR cells which can eﬀectively remove drugs from
the cell interior, preventing drug accumulation and compro-
mising treatment eﬃcacy. To address this challenge, one
strategy has been the co-delivery of anti-cancer drugs and
specic inhibitors against such eﬄux transporters to increase
the drug accumulation and improve treatment eﬃcacy.2
Another strategy has been the development of nanoscale drug
formulations (i.e. nanomedicines) which have completely
diﬀerent cell entry mechanisms from free drugs (e.g. endocy-
tosis vs. diﬀusion) and can deliver their drug payloads deep into
the cell interior.3 As a result, nanomedicines can bypass the
drug resistance mechanisms of MDR cells, leading to improved
treatment eﬃcacy. Furthermore, two or more diﬀerent drugs
can also be combined to exploit the synergy of multi-drug
treatment.3 Despite signicant research, the full potentials of
synergistic treatment is rather diﬃcult to realise because of the
diﬀerent drug release kinetics, making simultaneous co-
delivery and release of multiple drugs in target cells diﬃcult. To
address this challenge, herein we have proposed a new
approach where a PEGylated amphiphilic drug molecule
micelle is directly employed as the carrier for a second hydro-
phobic drug, leading to convenient loading and simultaneous
intracellular release of two diﬀerent drugs (Scheme 1) to maxi-
mise the synergy of dual-drug treatment. We show that these
novel dual-drug loaded micelles are highly eﬀective against the
MCF-7/ADR cell line, a MDR human breast cancer cell model.
Scheme 1 shows the schematics of our approach and the
proposed working mechanism. Firstly, hydrophobic rapamycin
is PEGylated via an ester bond formation to yield mPEG–SA–
rapamycin, turning rapamycin amphiphilic.5 mPEG–SA–rapa-
mycin is then exploited for micelle assembly with paclitaxel, a
second potent hydrophobic anticancer drug widely used in
clinical treatment of breast, ovarian, colon, bladder, lung, and
Scheme 1 Schematics of the fabrication and intracellular drug release
of PTX-loaded mPEG–SA–rapamycin micelles. Rapamycin is conju-
gated to PEG via an acid-liable ester bond to obtain amphiphilic
mPEG–SA–rapamycin which then self-assemble into a micelle in the
presence of paclitaxel, leading to simultaneous paclitaxel loading in
the core. After cell uptake, hydrolysis of the ester bonds between PEG
and rapamycin under the acidic intracellular compartments (e.g.
endosome/lysosome) leads to the micelle disassembly, triggering the
simultaneous release of both paclitaxel and rapamycin for synergistic
dual-drug therapy.
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head and neck cancers,6 yielding paclitaxel loaded rapamycin–
PEG micelles (Scheme 1, le). The loading of paclitaxel is
presumably through hydrophobic van der Waals interactions
between the hydrophobic paclitaxel and paramycin moieties,
forming dual-drug loaded hydrophobic micelle cores. Aer
uptake, the micelles are internalised into endosomes, which are
gradually acidied following the natural endosomal maturation
process, triggering the cleavage of the acid-labile ester linkage
between the PEG and rapamycin and the break up of the
micelles. As a result, paclitaxel and rapamycin are released
simultaneously inside the intracellular compartments, which
can then diﬀuse across the endo-/lyso-somal membranes into
cytosol and/or nucleus to exert their therapeutic functions. The
simultaneous intracellular release of both drug loads provides
an ideal situation for maximising the synergy of dual-drug
treatment.
PEGylated rapamycin is chosen as the model amphiphilic
drug carrier here because it is a hydrophobic macrolide with
useful immune suppressing functions. It has been used clini-
cally to reduce rejection in organ transplantation and also used
as a coronary stent coating. Recently, rapamycin was found to
have broad activities against lung, cervix, colon and breast
cancers.4 It has also been combined with paclitaxel to exploit
combinational therapy. For example, Shafer et al. found that
rapamycin potentiated the eﬀects of paclitaxel in endometrial
cancer cells through inhibition of cell proliferation and induc-
tion of apoptosis, and potentially increased polymerization and
acetylation of tubulin. Their results suggest that the combined
rapamycin–paclitaxel treatment may be benecial for endome-
trial cancer treatment.7 Moreover, Mishra et al. found that
paclitaxel–rapamycin dual-drug loaded poly(ethylene glycol)-
block-poly(D,L-lactic acid) (PEG-b-PLA) micelles had good anti-
angiogenic eﬀects at the cellular level.8 However, such studies
were either based on the physical mixture or co-encapsulated
paclitaxel–rapamycin, it is diﬃcult to achieve co-delivery and
simultaneously release both drugs inside target cells to maxi-
mise their synergy.
mPEG–SA–rapamycin was prepared by a standard dicyclo-
hexylcarbodiimide/dimethylaminopyridine based ester
coupling chemistry. Briey, mono-methoxyl PEG (MW ¼ 2000)
was reacted with succinic anhydride to yield methoxyl-poly-
(ethylene glycol)–succinic acid (mPEG–SA), which was then
coupled to rapamycin via esterication to form mPEG–SA–
rapamycin (see Scheme S2, ESI† for details). Each mPEG–SA–
rapamycin molecule contains a hydrophilic PEG chain and a
hydrophobic rapamycin moiety as conrmed by its NMR spec-
trum and TLC analysis (Fig. S1, ESI†). The equivalent rapamycin
weight loading in mPEG–SA–rapamycin is 30%. mPEG–SA–
rapamycin is highly soluble in water, 16.7 mg mL1 (or 5.0 mg
mL1 rapamycin equivalent), which is 1900 fold higher than
free rapamycin (2.6 mg mL1). PEGylation is one of the most
eﬀective and widely used approaches to improve solubility and
bioavailability of hydrophobic drugs.5 Besides, the amphiphilic
nature of mPEG–SA–rapamycin makes it easily self-assemble
into uniform, nanosized micelles in water with a hydrodynamic
diameter of 56  3 nm (polydispersity index (PDI) ¼ 0.132, see
ESI, Fig. S1†). It has a low critical micelle concentration (CMC)
of only 11.4 mg mL1.
The mPEG–SA–rapamycin micelles can be used as a carrier
for other hydrophobic drugs, providing a unique opportunity
for exploiting the synergy of dual-/multi-drug therapy. Here
paclitaxel was selected as the second anticancer drug because it
is hydrophobic and highly eﬀective against a wide range of
human cancers. Paclitaxel was encapsulated into the mPEG–
SA–rapamycin micelles with a high loading eﬃciency (93.3 
1.7%) by a simple solid dispersion method without any addi-
tional surfactants or additives (see ESI† for details). Encapsu-
lation of hydrophobic paclitaxel into the hydrophobic core led
to a considerable increase of micelle hydrodynamic size from
56 to 94 nm, but retained a similar size uniformity (PDI ¼
0.175). Importantly, paclitaxel encapsulation was found to
improve the micelle stability signicantly: the paclitaxel-loaded
micelles can be lyophilized and then reconstituted into clear
aqueous solutions without observable change of hydrodynamic
size, presumably because the strong attractive hydrophobic
interactions between the encapsulated paclitaxel and rapamy-
cin greatly stabilise the micelle cores. It also retained a very
similar zeta potential (11.2  1.2 mV) as the parent micelle
(10.6  2.0 mV). The weight loading of paclitaxel in the micelle
was 8.4  0.1%, while the equivalent rapamycin loading was
27.5%, beneted from the micelles made of the PEGylated drug
molecules.
Nanomedicines are mostly taken up by cells via endocytosis,
and hence will be exposed to a gradually increasing acidic
environment as a result of the natural endosomal maturation
process. Here the in vitro drug release proles were studied at
pH 7.4 and 5.0. The release proles for both rapamycin and
paclitaxel were pH sensitive: rapid releases were found at pH 5.0
(similar to that of late endosome or lysosome) where 90% of
the drugs were released in the rst 10 h. At pH 7.4 (normal
physiological pH), the drug release was much slower, where
maximum release was not reached until aer 72 h (Fig. 1). The
rapid release observed at pH 5.0 is likely due to the eﬀective
cleavage of the acid-labile ester linkage between the rapamycin
and PEG under such pH, leading to micelle destruction and
hence release of both drugs. The fact that both drugs are rapidly
and simultaneously released at pH 5.0 makes our micelle
system well-suited for intracellular co-delivery of paclitaxel/
rapamycin by exploiting the gradual acidication of the natural
endosomal traﬃcking/maturation process, which should
benet and maximise the synergy of dual-drug combinational
treatment.
Eﬀective removal of therapeutics from the cell interior by
over-expressed eﬄux transporters is a major cause of MDR in
cancer cells. Here we have evaluated the uptake and eﬄux of the
mPEG–SA–rapamycin micelles encapsulated with Rhodamine
6G (R6G) on the human breast cancer cells, MCF-7 (drug-
sensitive) and MCF-7/ADR (drug-resistant) by monitoring the
cellular R6G uorescence aer treatment via ow cytometry.
R6G is a suitable uorescence probe because it is a substrate for
p-glycoprotein, a major eﬄux transporter of MDR cells. Fig. 2A
shows that the R6G uorescence in MCF-7 cells is much
stronger than that of the MCF-7/ADR cells throughout the 24 h
This journal is © The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 1204–1207 | 1205
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incubation period with free R6G, indicating much less accu-
mulation of R6Gs in the MCF-7/ADR cells over the MCF-7 cells.
This agrees well with that the over-expressed p-glycoproteins on
the MDR cell surface can eﬀectively eﬄux internalised R6Gs,
preventing its intracellular accumulation. At 24 h, the R6G
intensity ratio between the drug-sensitive and -resistant cells
was106 fold with free R6G treatment (530 vs. 5). This ratio was
decreased to 9 fold with the R6G-micelle treatment (630 vs.
70), suggesting a dramatically decreased eﬄux ability for the
MCF-7/ADR cells against the R6G-micelles. Moreover, the
micelle treated MCF-7/ADR cells yielded a R6G uorescence
intensity 14 times as strong as those treated by free R6G, sug-
gesting that the micelles may have good potential for over-
coming drug resistance in the MCF-7/ADR cells. Consistent with
this observation, the R6G eﬄux rate for the R6G-micelle treated
MCF-7/ADR cells was also signicantly lower than those treated
with free R6G (Fig. 2B), presumably because the micelle
encapsulation completely altered the cell entry pathway for R6G
(endocytosis rather than diﬀusion), allowing the R6G payload to
be delivered and released deeply into the cell interior, signi-
cantly reducing the eﬃciency of eﬄux transporters located on
the MCF-7/ADR cell membranes.
The antitumor mechanism of rapamycin is to bind FKBP12
and inhibit mTOR, a central cell growth and proliferation
regulator. mTOR inhibition results in cell-cycle arrest in the G1
phase. In addition, rapamycin also blocks NF-nB activation and
may sensitize drug-resistant cells to chemotherapeutic treat-
ment. Quantitative analysis of the cell cycle distribution
revealed that only 56.79% of the untreated cells were in the G0/
G1 phase, which was increased to 69.42% and 68.14% aer
treatments with rapamycin and mPEG–SA–rapamycin respec-
tively (see ESI, Table S1†). This suggests that both rapamycin
and mPEG–SA–rapamycin have the same antitumor mecha-
nism, i.e. blocking cell cycle progression from the G1 to S phase.
Hence the antitumor eﬀect of mPEG–SA–rapamycin may origi-
nate from free rapamycin aer hydrolysis, which is in good
agreement with the proposed action mechanism shown in
Scheme 1.
Both rapamycin and mPEG–SA–rapamycin inhibited the
MCF-7 cell growth in a dose-dependent manner (ESI, Fig. S3†).
The IC50 values of rapamycin and mPEG–SA–rapamycin
against the MCF-7 cells were found to be 0.20 and 1.02 mg mL1
(for rapamycin or equivalent), respectively. The IC50 value of
mPEG–SA–rapamycin against MCF-7 cells is comparable to that
of a PEGylated rapamycin against the CRL 1739 human gastric
adenocarcinoma cell lines (1 mg mL1) recently reported by
Kumar and Lokesh.9 This indicates that PEGylated rapamycin
has broad antitumor activities against diﬀerent types of cancer
cells. The cytotoxicity of mPEG–SA–rapamycin against MCF-7
cells was lower than that of free rapamycin. However, their
cytotoxicity results against the MCF-7/ADR cells were exactly the
Fig. 1 Release proﬁles for rapamycin (A) and paclitaxel (B) from the
mPEG–SA–rapamycin micelles at pH 5.0 (red dots) and 7.4 (black
squares) in PBS containing 1% Tween-80 at 37 C. Data are given as
mean  SD (n ¼ 3).
Fig. 2 (A) Uptake and (B) eﬄux of Rhodamine 6G-loaded mPEG–SA–
rapamycin micelles and free Rhodamine 6G by MCF/7 (black squares
and red dots) and MCF-7/ADR cells (blue triangles and pink inverted
triangles).
1206 | J. Mater. Chem. B, 2015, 3, 1204–1207 This journal is © The Royal Society of Chemistry 2015
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opposite: where mPEG–SA–rapamycin was more cytotoxic than
free rapamycin (IC50 values: 3.48 vs. 10.50 mg mL
1, see ESI
Table S2 and Fig. S4†). This result is consistent with the earlier
observation that the MCF-7/ADR cells are less eﬀective at
eﬄuxing the R6G–mPEG–SA–rapamycinmicelles than free R6G.
The resistance indexes of rapamycin and mPEG–SA–rapamycin
were 52.5 and 3.4, respectively, indicating that PEGylation of
rapamycin signicantly reduced the resistance of the MCF-7/
ADR cancer cells.
The IC50 values of the diﬀerent paclitaxel formulations
against the MCF-7 and MCF-7/ADR cells are summarised in
Table 1. Compared to the MCF-7 cells, the MDR MCF-7/ADR
cells are highly resistant to free paclitaxel treatment with a high
resistance index of 212, which is much higher than that against
rapamycin. Interestingly, a physically combined paclitaxel and
rapamycin treatment (1 : 3 w/w, similar to that of the drug ratio
in the paclitaxel loaded micelles) exhibited a good antitumor
synergy against the MCF-7 cells, with a 5.1 fold reduction (from
29.2 to 5.7 ng mL1) of the IC50 value for paclitaxel. This was
referred as the reversal index. The eﬀect was weaker for the
MCF-7/ADR cells, where a reversal index of 2.8 was obtained. It
is exciting to nd that the paclitaxel-loaded mPEG–SA–rapa-
mycin micelle is far more cytotoxic towards the MCF-7/ADR
cells than free paclitaxel: its IC50 value was 20.2 fold lower than
that of free drug (Table 1). This suggests that the paclitaxel-
loaded mPEG–SA–rapamycin micelles can overcome the pacli-
taxel resistance of MCF-7/ADR cells, allowing for eﬀective
treatment of MDR cancer at the cellular level. This result is fully
consistent with our earlier observation that the amount of R6G
successfully accumulated inside the MCF-7/ADR cells resulting
from the R6G-micelle treatment was 14 fold as high as that
treated with the free R6G.
In summary, we have shown that PEGylation of rapamycin
into a pH-sensitive mPEG–SA–rapamycin not only greatly
improved its water-solubility but also generated amphiphilicity,
allowing for convenient micelle assembly and encapsulation of
paclitaxel, a potent hydrophobic anticancer drug. The pacli-
taxel-loaded mPEG–SA–rapamycin nanosized micelles are
stable, water-soluble, having high drug loading and capable of
producing eﬃcient, pH-triggered simultaneous dual-drug
release, and hence provide an ideal solution for intracellular
dual-drug co-delivery to maximise eﬃcacy. The paclitaxel-
loaded micelles exhibited 20 fold higher potency against the
multidrug resistant MCF-7/ADR breast cancer cells over free
paclitaxel. Extending this system to other drugs may establish a
new general and eﬀective strategy for dual-/multi-drug combi-
national therapies, allowing for eﬀective treatment of the
challenging MDR cancer tumours.
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